ReviewPharmacoEconomics2017
The Cost of Relapse in Schizophrenia.
Review in PharmacoEconomics, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
43 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Can incentives improve antipsychotic adherence in major mental illness? A mixed-methods systematic review.BMJ open · 2022Pooled it
- The association between community mental health nursing and hospital admissions for people with serious mental illness: a systematic review.Systematic reviews · 2020Pooled it
- The association between relapse and the outcome of schizophrenia and recurrent psychotic disorders.The British journal of psychiatry : the journal of mental science · 2025Trial
- Patient and Healthcare Professional Preferences for Characteristics of Long-Acting Injectable Antipsychotic Agents for the Treatment of Schizophrenia.Advances in therapy · 2023Trial
- Using Passive Sensing to Predict Psychosis Relapse: An In-Depth Qualitative Study Exploring Perspectives of People With Psychosis.Schizophrenia bulletin · 2026Article
- The Role of Long-Acting Injectable Antipsychotics in the Early Treatment of Schizophrenia.CNS drugs · 2026Review
- Views of People With Psychosis About Algorithm-Based Relapse Prediction and Data Sharing: Qualitative Study.Journal of medical Internet research · 2026Article
- Relapse rate and predictors among people with severe mental illnesses at Debre Markos Comprehensive specialized hospital, Northwest Ethiopia: a prospective follow up study.European archives of psychiatry and clinical neuroscience · 2026Article
- The global economic burden of schizophrenia: an umbrella review of systematic reviews and meta-analyses with reconstructed primary-study cost data.Health economics review · 2026Review
- Therapeutic Adherence Promotion Program for Severe Mental Illness: The ADHERA Study Protocol.Behavioral sciences (Basel, Switzerland) · 2026Article
- The ILIA study: protocol for a randomized-controlled multicenter clinical trial on smartphone- and web-based relapse monitoring for patients with schizophrenia or schizoaffective disorder.European archives of psychiatry and clinical neuroscience · 2026Article
- Genetics to Improve Outcomes in Schizophrenia (GENios): A within-case molecular genetic study protocol.PloS one · 2026Article
- Risk of bias in routine mental health outcome data: the case of Health of the Nation Outcome Scales.BMJ mental health · 2025Article
- Utility of Digital Phenotyping Based on Wrist Wearables and Smartphones in Psychosis: Observational Study.JMIR mHealth and uHealth · 2025Observational
- Development and validation of a recurrence risk prediction model for elderly schizophrenia patients.BMC psychiatry · 2025Article
- Comprehensive Analysis of the Microbiome and Metabolome: Unveiling Interactions Between Intestinal Flora and Metabolites in Schizophrenia.Neuropsychiatric disease and treatment · 2025Article
- Influencing factors of the participation of patients with severe mental disorders in community health service management.Frontiers in public health · 2025Article
- Real-world healthcare resource utilization, costs, and predictors of relapse among US patients with incident schizophrenia or schizoaffective disorder.Schizophrenia (Heidelberg, Germany) · 2024Article
- Comparative Effectiveness of Antipsychotics in Patients With Schizophrenia Spectrum Disorder.JAMA network open · 2024Article
- Does Slow and Steady Win the Race? Rates of Antipsychotic Discontinuation, Antipsychotic Dose, and Risk of Psychotic Relapse.Schizophrenia bulletin · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionSchizophrenia is a chronic and debilitating mental illness characterised by periods of relapse that require resource intensive management. Quantifying the cost of relapse is central to the evaluation of the cost effectiveness of treating schizophrenia.
objectivesWe aimed to undertake a comprehensive search of the available literature on the cost of relapse.
methodsWe performed a search on multiple databases (MEDLINE, Embase, PsycINFO and Health Management Information Consortium) for any study reporting a cost of relapse or data from which such a cost could be calculated. Costs are reported in 2015 international dollars.
resultsWe found 16 studies reporting costs associated with relapse over a defined period of time and identified a cost associated with hospitalisation for relapse in 43 studies. Eight clinical decision analyses also provided cost estimates. Studies from the US report excess costs of relapse of $6033-$32,753 (2015 Purchasing Power Parity dollars [PPP$]) over periods of 12-15 months. European studies report excess costs of $8665-$18,676 (2015 PPP$) over periods of 6-12 months. Estimates of the cost of hospitalisation for relapse are more diverse, and associated with marked differences in typical length of stay across jurisdictions.
conclusionsWide ranges in the estimated cost of relapse may reflect differences in sample section and relapse definition as well as practice styles and differences in resource costs. Selection of the most appropriate cost estimate should be guided by the definition of relapse and the analysis setting.
Indexed as
Identifiers
28534254What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.